2024
ASO Visual Abstract: National Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer
Kim L, Moore M, Schneider E, Canner J, Ayyala H, Chen J, Anant P, Graetz E, Lynch M, Zanieski G, Gillego A, Valero M, Proussaloglou E, Berger E, Golshan M, Greenup R, Park T. ASO Visual Abstract: National Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer. Annals Of Surgical Oncology 2024, 1-1. DOI: 10.1245/s10434-024-16259-9.Peer-Reviewed Original ResearchNational Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer
Kim L, Moore M, Schneider E, Canner J, Ayyala H, Chen J, Anant P, Graetz E, Lynch M, Zanieski G, Gillego A, Valero M, Proussaloglou E, Berger E, Golshan M, Greenup R, Park T. National Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer. Annals Of Surgical Oncology 2024, 1-12. PMID: 39322830, DOI: 10.1245/s10434-024-16107-w.Peer-Reviewed Original ResearchHR patientsLymph nodesRate of neoadjuvant chemotherapyHospital admissionNational patterns of careEmergency departmentDecrease wound complicationsNeoadjuvant chemo-Hospital re-admissionNeoadjuvant chemotherapyIn-hospital admissionRate of reconstructionPerioperative outcomesPostoperative hematomaComplication ratePostoperative complicationsWound complicationsHome recoveryPatterns of careBreast cancerMastectomyEmergency room visitsMultivariate analysisComplicationsPatientsIncidence of Pathologic Nodal Disease in Clinically Node-Negative, Microinvasive or T1a Breast Cancers
Dey P, Kc M, Proussaloglou E, Khubchandani J, Kim L, Zanieski G, Park T, Lynch M, Gillego A, Valero M, Schneider E, Golshan M, Greenup R, Berger E. Incidence of Pathologic Nodal Disease in Clinically Node-Negative, Microinvasive or T1a Breast Cancers. Annals Of Surgical Oncology 2024, 1-8. PMID: 39240394, DOI: 10.1245/s10434-024-16124-9.Peer-Reviewed Original ResearchTriple-negative breast cancerClinically node-negativePathologically node-negativePN+ diseaseNode-negativeBreast cancerYears of ageNodal diseaseHR-/HER2Significant comorbiditiesEpidermal growth factor receptor 2-positiveOdds of node positivityRate of nodal diseaseTriple-positive breast cancerTriple positive breast cancerEarly-stage breast cancerHR-positive/HER2-negativePathologic nodal diseasePathologic nodal positivityPredictors of pN+T1a breast cancerHR-/HER2+Sentinel node biopsyNational Cancer DatabasePathologic nodal stageTailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations
Elghazaly H, Azim H, Rugo H, Cameron D, Swain S, Curigliano G, Harbeck N, Tripathy D, Arun B, Aapro M, Piccart M, Cardoso F, Gligorov J, Elghazawy H, Saghir N, Penault‐Llorca F, Perez E, Poortmans P, Abdelaziz H, El‐Zawahry H, Kassem L, Sabry M, Viale G, Al‐Sukhun S, Gado N, Leung J, Elarab L, Cardoso M, Karim K, Foheidi M, Elmaadawy M, Conte P, Selim A, Kandil A, Kamal R, Paltuev R, Guarneri V, Abulkhair O, Zakaria O, Golshan M, Orecchia R, ElMahdy M, Abdel‐Aziz A, Eldin N. Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations. Cancer 2024, 130: 3251-3271. PMID: 38985794, DOI: 10.1002/cncr.35389.Peer-Reviewed Original ResearchBreast cancerNeoadjuvant therapyManagement of early breast cancerEarly breast cancerIndividual patient managementDe-escalation strategiesModified Delphi approachBC expertsPostneoadjuvant treatmentSystemic therapyClinical evidencePatient managementConsensus recommendationsClinical situationsTherapyDe-escalationDelphi approachTherapy outcomeTreatment settingsCancerExpert opinionRecommendationsBreastConsensus
2022
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
Geyer C, Sikov W, Huober J, Rugo H, Wolmark N, O’Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo J, Metzger O, Dunbar M, Symmans W, Rastogi P, Sohn J, Young R, Wright G, Harkness C, McIntyre K, Yardley D, Loibl S. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals Of Oncology 2022, 33: 384-394. PMID: 35093516, DOI: 10.1016/j.annonc.2022.01.009.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerEvent-free survivalAddition of carboplatinNeoadjuvant chemotherapyOverall survivalHazard ratioBreast cancerEarly-stage triple-negative breast cancerPathological complete response rateRandomized phase III trialComplete response rateCyclophosphamide neoadjuvant chemotherapyManageable acute toxicitiesManageable safety profileSafety of additionUntreated stage IIStandard neoadjuvant chemotherapyPhase III trialsCo-primary endpointsLong-term efficacyAcute myeloid leukemiaWeekly paclitaxelPrimary endpointSecondary endpointsIII trials
2021
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O’Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans WF, Geyer CE, Loibl S, Stover DG. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. Npj Breast Cancer 2021, 7: 142. PMID: 34764307, PMCID: PMC8586340, DOI: 10.1038/s41523-021-00349-y.Peer-Reviewed Original ResearchTriple-negative breast cancerNeoadjuvant chemotherapyCohort studyBreast cancerInstability scoreGenomic instability scoreGermline BRCA mutation carriersPathologic complete response rateAddition of carboplatinComplete response rateStandard neoadjuvant chemotherapyLymph node statusBRCA mutation carriersGermline BRCA1/2 mutationsNegative breast cancerOverall cohortNode statusTreatment armsHigher oddsMutation carriersBRCA1/2 mutationsResponse rateCarboplatinPARP inhibitorsCancerExploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery
Knoerl R, Giobbie-Hurder A, Sannes TS, Chagpar AB, Dillon D, Dominici LS, Frank ES, Golshan M, McTiernan A, Rhei E, Tolaney SM, Winer EP, Yung RL, Irwin ML, Ligibel JA. Exploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery. Supportive Care In Cancer 2021, 30: 2027-2036. PMID: 34648061, DOI: 10.1007/s00520-021-06617-8.Peer-Reviewed Original ResearchConceptsCancer treatment-related symptomsPrehabilitation interventionsTreatment-related symptomsTime of enrollmentImpact of exerciseQuality of lifeBreast cancerGroup participantsPre-operative exerciseBreast cancer surgeryMind-body interventionsCognitive functioningOpportunity trialCancer surgeryOutcome measuresSecondary analysisOne monthSurgeryMeasures of qualityGroup comparisonsCancer diagnosisCancerWomenInterventionSignificant differencesInterim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery
Basu SS, Stopka SA, Abdelmoula WM, Randall EC, Gimenez-Cassina Lopez B, Regan MS, Calligaris D, Lu FF, Norton I, Mallory MA, Santagata S, Dillon DA, Golshan M, Agar NYR. Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery. Npj Breast Cancer 2021, 7: 116. PMID: 34504095, PMCID: PMC8429658, DOI: 10.1038/s41523-021-00318-5.Peer-Reviewed Original ResearchIntraoperative mass spectrometrySurgical marginsBreast cancerTime of surgeryInvasive breast cancerBreast cancer surgeryRegistered clinical trialsBreast cancer tissuesBreast cancer marginsClinical trial analysisPost-surgery analysisSuch resectionsCancer surgerySurgical specimensClinical trialsHistopathological determinationOptimal resectionUninvolved regionsCancer tissuesTumor breastBreast tumorsCandidate biomarkersLipidomic profilesPathological techniquesNormal tissues119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial
Loibl S, Sikov W, Huober J, Rugo H, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo J, Metzger O, Dunbar M, Symmans W, Geyer C. 119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial. Annals Of Oncology 2021, 32: s408. DOI: 10.1016/j.annonc.2021.08.400.Peer-Reviewed Original ResearchSurgical Management of Hereditary Breast Cancer
Berger ER, Golshan M. Surgical Management of Hereditary Breast Cancer. Genes 2021, 12: 1371. PMID: 34573353, PMCID: PMC8470490, DOI: 10.3390/genes12091371.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsChemopreventionFemaleGenetic Predisposition to DiseaseGenetic TestingHereditary Breast and Ovarian Cancer SyndromeHeterozygoteHumansMastectomyMutationPractice Guidelines as TopicProphylactic Surgical ProceduresSalpingo-oophorectomyConceptsHereditary breast cancerBreast cancerGenetic variant carriersSurgical risk reductionSurgical management optionsSurgical managementBreast/ovarian cancer susceptibility geneOvarian cancer susceptibility genesVariant carriersCancer susceptibility genesGenetic testingCancer treatmentCancerRisk reductionSusceptibility genesManagement optionsApocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer
Saridakis A, Berger ER, Harigopal M, Park T, Horowitz N, Le Blanc J, Zanieski G, Chagpar A, Greenup R, Golshan M, Lannin DR. Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer. Annals Of Surgical Oncology 2021, 28: 5610-5616. PMID: 34426884, DOI: 10.1245/s10434-021-10518-9.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalCancer-specific survivalHigh-grade tumorsMolecular subtypesApocrine carcinomaBreast cancerBetter survivalHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Triple-negative breast cancerRare breast cancerEnd Results (SEER) databaseGrowth factor receptor 2Triple-negative patientsTriple-negative cancersLow-grade tumorsFactor receptor 2Life table methodApocrine tumorsLuminal patientsWorse survivalClinicopathologic featuresResults databaseAggressive featuresReceptor 2Immunotherapy Treatment for Triple Negative Breast Cancer
Berger ER, Park T, Saridakis A, Golshan M, Greenup RA, Ahuja N. Immunotherapy Treatment for Triple Negative Breast Cancer. Pharmaceuticals 2021, 14: 763. PMID: 34451860, PMCID: PMC8401402, DOI: 10.3390/ph14080763.Peer-Reviewed Original ResearchTriple-negative breast cancerImmune related adverse eventsBreast cancerMetastatic settingMetastatic triple-negative breast cancerEarly breast cancer settingImmune checkpoint inhibitor therapyBreast cancer settingCheckpoint inhibitor therapyRelated adverse eventsLocal recurrence rateHigh-risk subtypesNegative breast cancerDevelopment of biomarkersTypes of cancerImmunotherapy useAdverse eventsCheckpoint therapyOverall survivalStandard therapySystemic treatmentInhibitor therapyDismal prognosisImmunotherapy treatmentRecurrence rateHow did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?
Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.Peer-Reviewed Original ResearchUse of NTNeoadjuvant therapyEarly pandemic periodBreast cancerNon-metastatic breast cancerPractice settingsEarly pandemicFlatiron Health databaseNeoadjuvant endocrine therapyTechnology-enabled abstractionSame period one yearSimilar clinicopathologic featuresLongitudinal electronic health recordsPeriod one yearElectronic health recordsTNBC subsetEndocrine therapyPatient ageTN patientsClinicopathologic featuresContemporary cohortClinical stageCancer clinicCancer managementHigh riskAssociation of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Filho OM, Stover DG, Asad S, Ansell PJ, Watson M, Loibl S, Geyer CE, Bae J, Collier K, Cherian M, O’Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Symmans WF. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. JAMA Oncology 2021, 7: 603-608. PMID: 33599688, PMCID: PMC7893540, DOI: 10.1001/jamaoncol.2020.7310.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerPathologic complete responseNeoadjuvant chemotherapyGene expression-based molecular subtypesComplete responseMolecular subtypesBreast cancerClinical trialsSecondary analysisStage IIEnd pointAddition of carboplatinClinical stage IIDe-escalate therapyHigh pCR ratePrespecified end pointPrespecified secondary analysisSecondary end pointsStandard neoadjuvant chemotherapySimilar baseline characteristicsSubset of patientsT cell infiltrationRandomized clinical trialsTumor cell proliferationWhole transcriptome RNA sequencingSurvival Benefits Associated with Surgery in Patients with Metastatic Breast Cancer by Breast Cancer Subtype
Han H, . T, Yu J, Golshan M, Hsu H, Chu C, Hong Z, Fu C, Chou Y, Dai M, Liao G. Survival Benefits Associated with Surgery in Patients with Metastatic Breast Cancer by Breast Cancer Subtype. Journal Of Cancer Science And Clinical Therapeutics 2021, 05 DOI: 10.26502/jcsct.5079127.Peer-Reviewed Original Research
2020
Omission of Surgical Axillary Lymph Node Staging in Patients with Tubular Breast Cancer
Özkurt E, Wong S, Rhei E, Golshan M, Brock J, Barbie TU. Omission of Surgical Axillary Lymph Node Staging in Patients with Tubular Breast Cancer. Annals Of Surgical Oncology 2020, 28: 2589-2598. PMID: 33078312, DOI: 10.1245/s10434-020-09223-w.Peer-Reviewed Original ResearchConceptsInvasive ductal carcinomaER-positive invasive ductal carcinomasSurgical axillary stagingNational Cancer DatabaseTubular carcinomaLN involvementAxillary stagingOverall survivalDuctal carcinomaGrade IBreast cancerPositive invasive ductal carcinomaAxillary lymph node stagingKaplan-Meier survival curvesAxillary LN involvementFavorable breast cancerLN-positive diseasePropensity-matched analysisKaplan-Meier methodLymph node metastasisLymph node stagingTubular breast cancerLN diseaseNCDB cohortNodal involvementA randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).
Khan S, Zhao F, Solin L, Goldstein L, Cella D, Basik M, Golshan M, Julian T, Pockaj B, Lee C, Razaq W, Sparano J, Babiera G, Dy I, Jain S, Silverman P, Fisher C, Tevaarwerk A, Wagner L, Sledge G. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). Journal Of Clinical Oncology 2020, 38: lba2-lba2. DOI: 10.1200/jco.2020.38.18_suppl.lba2.Peer-Reviewed Original ResearchOptimal systemic therapyIntact primary tumorEarly local therapyLocoregional treatmentRecurrence/progressionOverall survivalSystemic therapyLocal therapyBreast cancerDe novo stage IV breast cancerDe novo metastatic breast cancerFACT-B Trial Outcome IndexNovo metastatic breast cancerRandomized phase III trialStage IV breast cancerCox proportional hazards modelInitial systemic therapyLocal disease progressionLocoregional disease controlMonths post randomizationYear OS ratesStage IV diseaseStage IV patientsPhase 3 trialPhase III trials
2019
Magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer
Golshan M, Wong S, Loibl S, Huober J, O'Shaughnessy J, Rugo H, Wolmark N, McKee M, Maag D, Sullivan D, Metzger-Filho O, Von Minckwitz G, Geyer C, Sikov W, Untch M. Magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer. European Journal Of Surgical Oncology 2019, 45: e12-e13. DOI: 10.1016/j.ejso.2018.10.075.Peer-Reviewed Original Research
2018
Prognostic role of lymphovascular invasion and lymph node status among breast cancer subtypes
Liao G, Hsu H, Chu C, Hong Z, Fu C, Chou Y, Golshan M, Dai M, Chen T, De-Chian C, Tsai W, Pan C, Hsu K, Kao E, Hsu Y, Chang T, Yu J. Prognostic role of lymphovascular invasion and lymph node status among breast cancer subtypes. Journal Of Medical Sciences 2018, 38: 54-61. DOI: 10.4103/jmedsci.jmedsci_105_17.Peer-Reviewed Original ResearchRecurrent-free survivalBreast cancer subtypesLymph node statusLymphovascular invasionOverall survivalImportant prognostic factorLymph nodesPrognostic factorsHuman Investigation CommitteeLuminal HER2 subtypeNode statusHER2 subtypeBreast cancerSignificant differencesCancer subtypesLymph node involvementYear of diagnosisInstitutional review board approvalKaplan-Meier analysisTriple-negative subtypeMultivariate survival analysisCox proportional hazardsDate of deathReview board approvalSignificant independent relationship
2017
170P Impact of neoadjuvant therapy (NT) and pathological complete response (pCR) on breast-conserving surgery (BCS) in patients (pts) with breast cancer (BC): A meta-analysis
Criscitiello C, Golshan M, Barry W, Viale G, Wong S, Santangelo M, Curigliano G. 170P Impact of neoadjuvant therapy (NT) and pathological complete response (pCR) on breast-conserving surgery (BCS) in patients (pts) with breast cancer (BC): A meta-analysis. Annals Of Oncology 2017, 28: v50-v51. DOI: 10.1093/annonc/mdx362.020.Peer-Reviewed Original Research